215 related articles for article (PubMed ID: 26908738)
21. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit M; Brisson M; Laprise JF; Choi YH
BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
[TBL] [Abstract][Full Text] [Related]
22. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
23. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
24. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
26. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach.
Vanni T; Luz PM; Foss A; Mesa-Frias M; Legood R
Vaccine; 2012 Jul; 30(32):4866-71. PubMed ID: 22652405
[TBL] [Abstract][Full Text] [Related]
27. Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
Simoens S; Bento-Abreu A; Merckx B; Joubert S; Vermeersch S; Pavelyev A; Varga S; Morais E
Front Pharmacol; 2021; 12():628434. PubMed ID: 33912045
[No Abstract] [Full Text] [Related]
28. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Tantitamit T
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670561
[TBL] [Abstract][Full Text] [Related]
30. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
31. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.
Cheung TH; Cheng SSY; Hsu D; Wing-Lei Wong Q; Pavelyev A; Sukarom I; Saxena K
Hum Vaccin Immunother; 2023 Aug; 19(2):2184605. PubMed ID: 37183965
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.
Palmer C; Dolk C; Sabale U; Wang W; Saxena K
Expert Rev Vaccines; 2024; 23(1):312-323. PubMed ID: 38417025
[TBL] [Abstract][Full Text] [Related]
33. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
34. Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.
Daniels V; Saxena K; Patterson-Lomba O; Gomez-Lievano A; Saah A; Luxembourg A; Velicer C; Chen YT; Elbasha E
Vaccine; 2022 Mar; 40(14):2173-2183. PubMed ID: 35232593
[TBL] [Abstract][Full Text] [Related]
35. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
[TBL] [Abstract][Full Text] [Related]
36. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
38. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
Termrungruanglert W; Khemapech N; Vasuratna A; Havanond P; Deebukkham P; Kulkarni AS; Pavelyev A
PLoS One; 2021; 16(2):e0245894. PubMed ID: 33571186
[TBL] [Abstract][Full Text] [Related]
39. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.
Laprise JF; Markowitz LE; Chesson HW; Drolet M; Brisson M
J Infect Dis; 2016 Sep; 214(5):685-8. PubMed ID: 27234416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
